Home > Products > CD20 & CD22 > Recombinant Human Anti-CD20 x Human Anti-CD22 Bispecific Antibody (scFv4-Ig)

Recombinant Human Anti-CD20 x Human Anti-CD22 Bispecific Antibody (scFv4-Ig)  (CAT#: FVTIG-H226)

Recombinant Anti-CD20 x Anti-CD22 Bispecific Antibody (scFv4-Ig) is an appended IgG format, which includes four scFv moieties at the N-termini of the constant regions. It is a bivalent homodimer, in which one anti-CD20 scFv is fused to the CH1 domain of a heavy chain and another anti-CD22 scFv to the CL domain of a light chain, or vice versa. The resulting leads to 2+2 antigen-binding valency. This BsAb is designed for the research of Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease therapy.
Datasheet INQUIRY

Specifications

Targets
CD20 & CD22
Type
Appended IgGs
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease

Targets

Target 1
CD20
Gene ID
UniProt ID
Alternative Names
MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1
Target 2
CD22
Gene ID
UniProt ID
Alternative Names
CD22; CD22 molecule; Cluster of differentiation 22; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CD20 & CD22"
See other bsAb targets related to "CD22"

See other bsAb targets related to "CD20"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD20 x Human Anti-CD22 Bispecific Antibody (scFv4-Ig) (FVTIG-H226). Click the button below to contact us or submit your feedback about this product.